Sugi Predict

Sugi Predict / Compounds / SCHEMBL166743

SCHEMBL166743

SCHEMBL166743

COC(=O)c1cc(O)ccc1I

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 6/20 0.67
▸ CA1 P00915 6/20 0.67
▸ CA2 P00918 6/20 0.67
▸ CA7 P43166 6/20 0.67
▸ CA9 Q16790 6/20 0.67
▸ CA14 Q9ULX7 6/20 0.67
▸ PDK2 Q15119 1/20 0.61
▸ PDK4 Q16654 1/20 0.61
▸ LMNA P02545 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ GAA P10253 2/20 0.44
▸ AR P10275 1/20 0.44
▸ EGFR P00533 3/20 0.44
▸ PTGS2 P35354 1/20 0.42
▸ ESR2 Q92731 1/20 0.42
▸ MAPT P10636 2/20 0.42
▸ CFTR P13569 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23312074 0.85 CA12 (0.67) CA12CA1CA2CA7CA9
SCHEMBL31017541 0.85 CA12 (0.67) CA12CA1CA2CA7CA9
SCHEMBL28430334 0.83 KDM4E (0.60) CA12CA1CA2CA7CA9
SCHEMBL1277539 0.82 CA12 (0.44) CA12CA1CA2CA7CA9
SCHEMBL158999 0.82 CA12 (0.74) CA12CA1CA2CA7CA9
SCHEMBL2747430 0.81 CA12 (0.57) CA12CA1CA2CA7CA9
SCHEMBL27707943 0.81 KDM4E (0.58) CA12CA1CA2CA7CA9
SCHEMBL1421927 0.81 CYP46A1 (0.53) CA12CA1CA2CA7CA9
SCHEMBL31506855 0.81 CYP46A1 (0.53) CA12CA1CA2CA7CA9
Methyl 2,5-Dihydroxybenzoate SCHEMBL29457577 0.80 CA12 (1.00) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119874686-A Deuterated benzimidazole derivative and preparation method and application thereof 石药集团中奇制药技术（石家庄）有限公司 2025-04-25 — — CN disclosed
EP-2611771-B1 SUBSTITUTED HETEROARYL- AND ARYLALKYNYL BENZENE DERIVATIVES AS ACC-INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES BOEHRINGER INGELHEIM INT (DE) 2016-11-23 — — EP disclosed
EP-2611771-B1 SUBSTITUTED HETEROARYL- AND ARYLALKYNYL BENZENE DERIVATIVES AS ACC-INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES BOEHRINGER INGELHEIM INT (DE) 2016-11-23 — — EP disclosed
EP-2614054-B1 ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INT (DE) 2014-11-19 — — EP disclosed
US-8877754-B2 Compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-04 — — US disclosed
US-8835472-B2 Compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-16 — — US disclosed
US-8835472-B2 Compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-16 — — US disclosed
US-8835472-B2 Compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-16 — — US disclosed
EP-2614054-A1 ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Boehringer Ingelheim International GmbH (DE) 2013-07-17 — — EP disclosed
EP-2611771-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Boehringer Ingelheim International GmbH (DE) 2013-07-10 — — EP disclosed
US-20050176684-A1 Novel aryl fructose-1,6-bisphosphatase inhibitors BOOKSER BRETT C (US) 2005-08-11 — — US disclosed
US-6919322-B2 Phenyl Phosphonate Fructose-1,6-Bisphosphatase Inhibitors METABASIS THERAPEUTICS, INC. (US) 2005-07-19 — — US disclosed
CN-1599612-A Combination of FBP enzyme inhibitor and antidiabetic agent for treating diabetes METABASIS THERAPEUTICS INC (US) 2005-03-23 — — CN disclosed
CN-1516705-A Novel arylfructose-1, 6-bisphosphatase inhibitors ֢�����ƹ�˾ 2004-07-28 — — CN disclosed
EP-1372660-A2 A COMBINATION OF FBPASE INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES Metabasis Therapeutics, Inc. (US) 2004-01-02 — — EP disclosed
US-20030073728-A1 Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes METABASIS THERAPEUTICS, INC. 2003-04-17 — — US disclosed
EP-1265907-A2 NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS Metabasis Therapeutics, Inc. (US) 2002-12-18 — — EP disclosed
US-20020040014-A1 Novel aryl fructose-1,6-Bisphosphatase inhibitors METABASIS THERAPEUTICS, INC. 2002-04-04 — — US disclosed
WO-2002003978-A2 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES METABASIS THERAPEUTICS, INC. (US) 2002-01-17 — — WO disclosed
WO-2001066553-A2 NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS METABASIS THERAPEUTICS, INC. (US) 2001-09-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073728-A1 Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes FBP1, ALDOA, G6PC1 CA12 2664/4885CA1 2648/4885CA2 974/4885
US-20020040014-A1 Novel aryl fructose-1,6-Bisphosphatase inhibitors FBP1, SLC5A1, G6PC1 CA12 4493/4885CA1 4016/4885CA2 2484/4885
US-20050176684-A1 Novel aryl fructose-1,6-bisphosphatase inhibitors FBP1, G6PC1, SLC5A1 CA12 4591/4885CA1 4224/4885CA2 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.